1887

Abstract

Natural killer (NK) cells are a major component of the host innate immune defence against various pathogens. Several viruses, including (HIV-1), have developed strategies to evade the NK-cell response. This study was designed to evaluate whether HIV-1 could interfere with the expression of NK cell-activating ligands, specifically the human leukocyte antigen (HLA)-I-like MICA and ULBP molecules that bind NKG2D, an activating receptor expressed by all NK cells. Results show that the HIV-1 Nef protein downmodulates cell-surface expression of MICA, ULBP1 and ULBP2, with a stronger effect on the latter molecule. The activity on MICA and ULBP2 is well conserved in Nef protein variants derived from HIV-1-infected patients. In HIV-1-infected cells, cell-surface expression of NKG2D ligands increased to a higher extent with a Nef-deficient virus compared with wild-type virus. Mutational analysis of Nef showed that NKG2D ligand downmodulation has structural requirements that differ from those of other reported Nef activities, including HLA-I downmodulation. Finally, data demonstrate that Nef expression has functional consequences on NK-cell recognition, causing a decreased susceptibility to NK cell-mediated lysis. These findings provide a novel insight into the mechanisms evolved by HIV-1 to escape from the NK-cell response.

Loading

Article metrics loading...

/content/journal/jgv/10.1099/vir.0.82125-0
2007-01-01
2024-03-19
Loading full text...

Full text loading...

/deliver/fulltext/jgv/88/1/242.html?itemId=/content/journal/jgv/10.1099/vir.0.82125-0&mimeType=html&fmt=ahah

References

  1. Arold S. T., Baur A. S. 2001; Dynamic Nef and Nef dynamics: how structure could explain the complex activities of this small HIV protein. Trends Biochem Sci 26:356–363 [CrossRef]
    [Google Scholar]
  2. Bauer S., Groh V., Wu J., Steinle A., Phillips J. H., Lanier L. L., Spies T. 1999; Activation of NK cells and T cells by NKG2D, a receptor for stress-inducible MICA. Science 285:727–729 [CrossRef]
    [Google Scholar]
  3. Baur A. 2004; Functions of the HIV-1 Nef protein. Curr Drug Targets Immune Endocr Metabol Disord 4:309–313 [CrossRef]
    [Google Scholar]
  4. Bonaparte M. I., Barker E. 2003; Inability of natural killer cells to destroy autologous HIV-infected T lymphocytes. AIDS 17:487–494 [CrossRef]
    [Google Scholar]
  5. Carl S., Greenough T. C., Krumbiegel M., Greenberg M., Skowronski J., Sullivan J. L., Kirchhoff F. 2001; Modulation of different human immunodeficiency virus type 1 Nef functions during progression to AIDS. J Virol 75:3657–3665 [CrossRef]
    [Google Scholar]
  6. Casartelli N., Di Matteo G., Argentini C. & 7 other authors 2003a; Structural defects and variations in the HIV-1 nef gene from rapid, slow and non-progressor children. AIDS 17:1291–1301 [CrossRef]
    [Google Scholar]
  7. Casartelli N., Di Matteo G., Potesta M., Rossi P., Doria M. 2003b; CD4 and major histocompatibility complex class I downregulation by the human immunodeficiency virus type 1 nef protein in pediatric AIDS progression. J Virol 77:11536–11545 [CrossRef]
    [Google Scholar]
  8. Cerboni C., Mousavi-Jazi M., Wakiguchi H., Carbone E., Kärre K., Söderström K. 2001; Synergistic effect of IFN-gamma and human cytomegalovirus protein UL40 in the HLA-E-dependent protection from NK cell-mediated cytotoxicity. Eur J Immunol 31:2926–2935 [CrossRef]
    [Google Scholar]
  9. Chalupny N. J., Sutherland C. L., Lawrence W. A., Rein-Weston A., Cosman D. 2003; ULBP4 is a novel ligand for human NKG2D. Biochem Biophys Res Commun 305:129–135 [CrossRef]
    [Google Scholar]
  10. Chowers M. Y., Spina C. A., Kwoh T. J., Fitch N. J., Richman D. D., Guatelli J. C. 1994; Optimal infectivity in vitro of human immunodeficiency virus type 1 requires an intact nef gene. J Virol 68:2906–2914
    [Google Scholar]
  11. Cohen G. B., Gandhi R. T., Davis D. M., Mandelboim O., Chen B. K., Strominger J. L., Baltimore D. 1999; The selective downregulation of class I major histocompatibility complex proteins by HIV-1 protects HIV-infected cells from NK cells. Immunity 10:661–671 [CrossRef]
    [Google Scholar]
  12. Collins K. L., Chen B. K., Kalams S. A., Walker B. D., Baltimore D. 1998; HIV-1 Nef protein protects infected primary cells against killing by cytotoxic T lymphocytes. Nature 391:397–401 [CrossRef]
    [Google Scholar]
  13. Cosman D., Mullberg J., Sutherland C. L., Chin W., Armitage R., Fanslow W., Kubin M., Chalupny N. J. 2001; ULBPs, novel MHC class I-related molecules, bind to CMV glycoprotein UL16 and stimulate NK cytotoxicity through the NKG2D receptor. Immunity 14:123–133 [CrossRef]
    [Google Scholar]
  14. Deacon N. J., Tsykin A., Solomon A. & 17 other authors 1995; Genomic structure of an attenuated quasi species of HIV-1 from a blood transfusion donor and recipients. Science 270:988–991 [CrossRef]
    [Google Scholar]
  15. Doms R. W., Trono D. 2000; The plasma membrane as a combat zone in the HIV battlefield. Genes Dev 14:2677–2688 [CrossRef]
    [Google Scholar]
  16. Eger K. A., Unutmaz D. 2004; Perturbation of natural killer cell function and receptors during HIV infection. Trends Microbiol 12:301–303 [CrossRef]
    [Google Scholar]
  17. Gasser S., Orsulic S., Brown E. J., Raulet D. H. 2005; The DNA damage pathway regulates innate immune system ligands of the NKG2D receptor. Nature 436:1186–1190 [CrossRef]
    [Google Scholar]
  18. Gervaix A., West D., Leoni L. M., Richman D. D., Wong-Staal F., Corbeil J. 1997; A new reporter cell line to monitor HIV infection and drug susceptibility in vitro. Proc Natl Acad Sci U S A 94:4653–4658 [CrossRef]
    [Google Scholar]
  19. Geyer M., Fackler O. T., Peterlin B. M. 2001; Structure–function relationships in HIV-1 Nef. EMBO Rep 2:580–585 [CrossRef]
    [Google Scholar]
  20. Groh V., Wu J., Yee C., Spies T. 2002; Tumour-derived soluble MIC ligands impair expression of NKG2D and T-cell activation. Nature 419:734–738 [CrossRef]
    [Google Scholar]
  21. Grzesiek S., Stahl S. J., Wingfield P. T., Bax A. 1996; The CD4 determinant for downregulation by HIV-1 Nef directly binds to Nef. Mapping of the Nef binding surface by NMR. Biochemistry 35:10256–10261 [CrossRef]
    [Google Scholar]
  22. Hanna Z., Kay D. G., Rebai N., Guimond A., Jothy S., Jolicoeur P. 1998; Nef harbors a major determinant of pathogenicity for an AIDS-like disease induced by HIV-1 in transgenic mice. Cell 95:163–175 [CrossRef]
    [Google Scholar]
  23. Kirchhoff F., Greenough T. C., Brettler D. B., Sullivan J. L., Desrosiers R. C. 1995; Brief report: absence of intact nef sequences in a long-term survivor with nonprogressive HIV-1 infection. N Engl J Med 332:228–232 [CrossRef]
    [Google Scholar]
  24. Lanier L. L. 2005; NK cell recognition. Annu Rev Immunol 23:225–274 [CrossRef]
    [Google Scholar]
  25. Le Gall S., Erdtmann L., Benichou S., Berlioz-Torrent C., Liu L., Benarous R., Heard J. M., Schwartz O. 1998; Nef interacts with the mu subunit of clathrin adaptor complexes and reveals a cryptic sorting signal in MHC I molecules. Immunity 8:483–495 [CrossRef]
    [Google Scholar]
  26. Liu X., Schrager J. A., Lange G. D., Marsh J. W. 2001; HIV Nef-mediated cellular phenotypes are differentially expressed as a function of intracellular Nef concentrations. J Biol Chem 276:32763–32770 [CrossRef]
    [Google Scholar]
  27. Lodoen M. B., Lanier L. L. 2005; Viral modulation of NK cell immunity. Nat Rev Microbiol 3:59–69 [CrossRef]
    [Google Scholar]
  28. Maier R., Bartolomè-Rodrìguez M. M., Moulon C., Weltzien H. U., Meyerhans A. 2000; Kinetics of CXCR4 and CCR5 up-regulation and human immunodeficiency virus expansion after antigenic stimulation of primary CD4(+) T lymphocytes. Blood 96:1853–1856
    [Google Scholar]
  29. McMichael A. 1998; T cell responses and viral escape. Cell 93:673–676 [CrossRef]
    [Google Scholar]
  30. Pende D., Cantoni C., Rivera P. & 8 other authors 2001; Role of NKG2D in tumor cell lysis mediated by human NK cells: cooperation with natural cytotoxicity receptors and capability of recognizing tumors of nonepithelial origin. Eur J Immunol 31:1076–1086 [CrossRef]
    [Google Scholar]
  31. Peterlin B. M., Trono D. 2003; Hide, shield and strike back: how HIV-infected cells avoid immune eradication. Nat Rev Immunol 3:97–107 [CrossRef]
    [Google Scholar]
  32. Pross H. F., Callerwaert D., Rubin P. 1986; Assay for NK cell cytotoxicity – their values and pitfalls. In Immunobiology of Natural Killer Cells pp  2–20 Edited by Lotzova E., Herberman R. B. Boca Raton, FL: CRC Press;
    [Google Scholar]
  33. Raulet D. H. 2003; Roles of the NKG2D immunoreceptor and its ligands. Nat Rev Immunol 3:781–790 [CrossRef]
    [Google Scholar]
  34. Robertson M. J., Cochran K. J., Cameron C., Le J. M., Tantravahi R., Ritz J. 1996; Characterization of a cell line, NKL, derived from an aggressive human natural killer cell leukemia. Exp Hematol 24:406–415
    [Google Scholar]
  35. Rölle A., Mousavi-Jazi M., Eriksson M., Odeberg J., Söderberg-Nauclér C., Cosman D., Karre K., Cerboni C. 2003; Effects of human cytomegalovirus infection on ligands for the activating NKG2D receptor of NK cells: up-regulation of UL16-binding protein (ULBP)1 and ULBP2 is counteracted by the viral UL16 protein. J Immunol 171:902–908 [CrossRef]
    [Google Scholar]
  36. Salih H. R., Antropius H., Gieseke F., Lutz S. Z., Kanz L., Rammensee H. G., Steinle A. 2003; Functional expression and release of ligands for the activating immunoreceptor NKG2D in leukemia. Blood 102:1389–1396 [CrossRef]
    [Google Scholar]
  37. Schrager J. A., Marsh J. W. 1999; HIV-1 Nef increases T cell activation in a stimulus-dependent manner. Proc Natl Acad Sci U S A 96:8167–8172 [CrossRef]
    [Google Scholar]
  38. Schwartz O., Riviere Y., Heard J. M., Danos O. 1993; Reduced cell surface expression of processed human immunodeficiency virus type 1 envelope glycoprotein in the presence of Nef. J Virol 67:3274–3280
    [Google Scholar]
  39. Welte S. A., Sinzger C., Lutz S. Z., Singh-Jasuja H., Sampaio K. L., Eknigk U., Rammensee H. G., Steinle A. 2003; Selective intracellular retention of virally induced NKG2D ligands by the human cytomegalovirus UL16 glycoprotein. Eur J Immunol 33:194–203 [CrossRef]
    [Google Scholar]
http://instance.metastore.ingenta.com/content/journal/jgv/10.1099/vir.0.82125-0
Loading
/content/journal/jgv/10.1099/vir.0.82125-0
Loading

Data & Media loading...

This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error